COVID-19 Funds Flow To Startup In Bid To Restore US Pharmaceutical Manufacturing

Trump administration infuses Phlow with potentially $800m-plus for fully integrated domestic manufacture of essential medicines for COVID-19 and other crises. Key figures in new approaches to securing drugs and experts on China helped frame the project’s approach.

PS2005_Pharma Factory_266841464_1200
domestic us pharma manufacturing startup funded • Source: Shutterstock

The federal response to the coronavirus pandemic has put a Richmond, VA, start-up called Phlow Corp. in the role of preventing shortages of essential medicines and shielding the US market from global competition, particularly from China.

The decision the Health and Human Services Department announced 19 May to provide Phlow with $354m of COVID-19 response funding...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

More from Compliance